					In a series of Contracts		A			
OIP E INFORMATION DISCLOSURE CITATION					Docket Number (Optional) Army 178	Application Number 0/772,704				
					Army 1/8 0///2,704 Applicant(s)					
(Alex amount shoots if					Tsokos					
	4 2004				Filing Date February 5, 20		Group Art Unit			
Br.	٠.5	y	U.S.	. PATENT	DOCUMENTS					
·EXAMINER	THE SAME	NIINADEO		<u> </u>		7 21 455	21700 400	FILIN	G DATE	
INITIAL	REF	DOCUMENT NUMBER	DATE	<u> </u>	NAME	CLASS	SUBCLASS		OPRIATE	
			U.S. PATENT	: APPLICA	ATION PUBLICATIONS	J				
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
			FOREI	GN PATEN	NT DOCUMENTS					
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	YES	slation	
										
			1		.	 				
			1			<u> </u>				
			OTHER DO		(
Tenbrock, "Antisense cyclic adenosine 5'-monoshosphate response element modulator up-regulates IL-2 in T patients with systemic lupus erythematosus", Jour. of Immun. vol. 169, no. 8, 15 Oct. 2002, pages 4147-4152						in T cells f	rom			
JDS		panents with systems	upus erytueniatusu	18", Jour. (oi Immun. voi. 107, 110. 0,	15 Oct. 2004	!, pages 4147-41	52		
Database WPI, sect. Ch, Week 199929, Serwent PI & JP 11 123082 A, 11 May 1999, Abstract				rwent PUI	blications Ltd., London, G	B; Class Bo	4, AN 1999-340	518, XPOC)22904	
EXAMINEI	EXAMINER				DATE CONSIDERED					
EXAMINE	R: Initi	al if citation considered, whether	r or not citation is in (conformanc	ce with MPEP Section 609; D	raw line thro	ugh citation if not	in conform	ance and	
not consider	red. Inc	clude copy of this form with next	communication to ar	pplicant.						

Form PTO-A820 (also form PTO-1449)

P09A/REV05

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

	والمناسب التعلق والمراجع والمراجع والمستعدد والمستعدد والمستعدد والمستعدد والمستعدد والمستعدد والمستعدد والمستعدد	والمكالين المساوي والمناوا						
		Docket Number (Optional) Army 178	Application Number 10/772,704					
INFO	ORMATION DISCLOSURE CITATION	Applicant(s)						
	(Use several sheets if necessary)	Tsokos Filing Date Group Art Unit						
		February 5, 2004	Group Art Umit					
*EXAMINER	OTHER DOCUMENTS (Including Author, Tit	tle, Date, Pertinent Pages, Etc.)						
INITIAL	Yoshimoto Keiko et al., "Antisense repression of TCR zeta chain alters cell proliferation and IL-2 production in Molt-4 cell line.", Arthritis and Rheumatism, vol. 42, no. 9, SUPPL., Sept. 1999, pages \$95							
JDS I	XP008034010 &63rd annual scientific meeting of the American College of Rheumatology and the 34th annual scientific; Boston, Mass. , Nov. 13-17, 1999 Abstract 146							
	Solumou E E et al. "Molecular basis of deficient IL Journal of Immunology (Baltimore, MD 1950) 15 N	March 2001, vol. 166, no. 6., päges 421	6					
	Liossis, et al. "Altered prttern of TCR/CD3-mediat lupus erythematosis" Journal of Clinical Investig							
		kammer et al., "Abnormal T lymphocyte signal transduction in systemic lymphocyte signal transduction in systemic lupus erythematosus." Cruuent Directoins In Autoimmunity. 2002, vol. 5, 2002, pages 131-150.						
	Herndon, et al., "Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity, Clinical Immunology (Orlando, FL) May 2002.							
	Database Biosis 'Online! Biosciences Information S the T-cell: Signaling defects and novel prospects for Database accession No. PREV2003300292284. Abst	ervice Philadelphia, PA US; May 2003 r the treatment of SLE." tract	3 (2003-05), Tsokos et al, "Re2wiring					
\downarrow	"Reconstitution of Deficient T cell receptor zeta chi	Database medline Online, US National Library of Medicine, Bethesda, MD, July 2003, Nambiar Madhussodana, et al, "Reconstitution of Deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with syt=stemic lupus erythematosus." abstract &Arthritis and Rheumatism., Jul 2003, vol. 48, no. 7, July 2003, pges 1948-1955.						
EXAMINER	/James Schultz/	DATE CONSIDERED 08/16/2006						
*EXAMINER: Inf	itial if citation considered, whether or not citation is in conforma	nce with MPEP Section 609; Draw line thr	ough citation if not in conformance and					

P09B/REV04

not considered. Include copy of this form with next communication to applicant.

				Docket Number (Optional) Application Number Army 178 /C/772, 764				<i>16</i> 4			
s - 02/	6 9 /2	B844	TION DISCLOSURE	CITATION		Applicant(s) Tsokos, et al.					
		(२०१२ वर्ग वर्ग वर्ग वर्ग वर्ग वर्ग वर्ग वर्ग			Filing Date 2 5 04		Group Art Unit			
	-				U.S. PAT	ENT DOCUMENTS					
•EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		_				··					
		 -									
		-		 	 				 		
		<u> </u>		<u> </u>					 		
				1			 		<u> </u>		
		 		 			 				
		-		 	 		 				
	-	 		 			1				
		 			†				† — —	!	
		 			+		†			•	
		Ц		<u> </u>	FOREIG	N PATENT DOCUMENTS		_1	<u></u>		
	REF	<u> </u>	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	Translation		
		\vdash		1	†				YES	NO	
		 		 	†		 		-		
		 	<u> </u>	1	 			<u> </u>	 	<u> </u>	
		 		 	+				 	 	
		-		 	+				 		
		<u></u>			OTHER	DOCUMENTS (Including	Author. Title.	Date, Pertinent Pa	ges, E(c.)	L	
JDS		A	Clin Immunol. 2002 Ma patients leads to increas WRAIR	ry: 103(2): 145-5 red levels of Inter		ansfer of p65 into T lymp romoter activity, Herndon			-	osus Tsokos,	
	\bot		Journal of Immunology	, (2002) NF-LR	Regulates t	he Expression of the Hum	ian Complem	ent Recentor 2	Gene. Tolo	ıay.	
лs		B			g						
EXAMINE	EXAMINER /James Schultz/			_	DATE CONSIDERED	08/16	08/16/2006				
EXAMINE considered.	R: Initi	ial if ci ie copy	tation considered, whether of this form with next com	or not citation is in munication to app	conforman	ce with MPEP Section 609; D)raw line throu	gh citation if not	in conforma	nce and not	